Best Small Cap Stocks this April 2026

Nexa Resources (NEXA) is an appealing option for investors seeking growth, boasting a remarkable projected EPS growth of 99.61% alongside a solid 1-year return of 62.40%. While the company offers a modest dividend yield of 1.37%, its strong performance and an AI Score of 7/10 indicate a favorable outlook, suggesting it is likely to outperform the market. Analysts have set a median price target of $11.10, reflecting a mix of cautious optimism, with ratings ranging from Sector Perform to Neutral from major banks.

Nexa Resources SA has an AI Score of 7/10, indicating a Buy rating and a 58% probability of outperforming the market in the next three months.

NexGen Energy has an average brokerage recommendation of 1.50, suggesting it is a Strong Buy.

Rocket Lab Corporation (RKLB) is capitalizing on a strong surge in stock price, thanks to lucrative government contracts and the promising commercialization of its Neutron platform. With a staggering one-year return of 240.28% and a remarkable five-year return of 428.95%, analysts have set a median 12-month price target of $84.00, reflecting a bullish sentiment despite a C- rating overall.

RKLB's stock has a 52-week range of $14.71 to $99.58.

Rocket Lab (NASDAQ: RKLB) has gained over 1,500% in the past three years, making it one of the top growth stocks.

In five years, Rocket Lab could emerge as a strong competitor to industry leaders like SpaceX, although its current high price-to-sales ratio suggests that much of this potential is already reflected in its valuation.

AXT Inc (AXTI) has delivered an impressive one-year return of 3913.55%, making it a standout in the semiconductor materials sector. Analysts have set a median price target of $23.00, with some ratings reflecting a mixed outlook—B. Riley Securities remains neutral, while Wedbush rates it as outperform. The stock currently presents a favorable buying opportunity, supported by positive short-term forecasts as it trends above long-term averages.

First Majestic Silver has a Strong Buy rating with a 71.05% probability of outperforming the market in the next three months, according to Danelfin AI.

AXTI shows a positive forecast as its short-term average is above the long-term average, indicating a general buy signal.

AXTI's recent price increase is attributed to positive momentum in AI and data-center optical supply chains, particularly related to indium phosphide substrates for high-speed connectivity.

Babcock & Wilcox Enterprises Inc (BW) has delivered an impressive one-year return of 1890.54%, showcasing its potential as a strong player in the industrial energy sector. With a consensus rating of Buy from analysts, including a range of price targets from $9.00 to $19.00, BW is positioned well for future growth, aiming for $769 million in revenue by 2029. Investors seeking exposure to a rapidly growing company may find BW an attractive option, especially given its promising revenue and earnings forecasts.

BW has a consensus rating of Buy from 3 analysts, with 33% recommending Strong Buy, 33% recommending Buy, and 33% suggesting Hold.

Bandwidth (BAND) has a consensus rating of Buy from 5 analysts, with 40% recommending Strong Buy, 20% recommending Buy, 20% suggesting Hold, and 20% advising Sell.

Babcock & Wilcox Enterprises projects $769 million in revenue and $21.2 million in earnings by 2029, requiring a 2.2% annual revenue growth and a significant earnings turnaround.

Nektar Therapeutics (NKTR) has delivered an impressive one-year return of 512.05%, making it a standout in the small-cap sector. Analysts are optimistic about its future, projecting revenue growth of 36.8% annually, significantly outpacing the broader US market. Currently, NKTR holds a median 12-month price target of $140.00, with strong "Buy" ratings from firms like Citigroup and B. Riley Securities, despite a lower overall analyst rating of D+.

NKTR's revenue is forecast to grow at 36.8% per year, significantly outpacing the US market growth rate of 10.4%.

Vyne Therapeutics (VYNE) has a consensus rating of Strong Buy from analysts.

Gold.com Inc (GOLD) is an attractive option for investors seeking a robust gold trading platform, boasting a remarkable 26.67% price change over the last twelve weeks and a promising projected EPS growth of 100%. With a 1-year return of 38.65% and a 5-year return of 118.11%, the stock shows strong performance potential. Analysts have set a median price target of $57.00, indicating confidence in its upward trajectory, with DA Davidson consistently maintaining a "Buy" rating.

If you had invested $10,000 in gold 20 years ago, it would have grown to approximately $65,967, reflecting an average annual return of 9.47%.

Relmada Therapeutics Inc (RLMD) has garnered significant attention with an impressive one-year return of 2057.72%, despite a slight decline of 1.68% over the past five years. Analysts project a median 12-month price target of $9.00, with a range between $8.00 and $10.00, reflecting a cautiously optimistic outlook. Recent upgrades from firms like Mizuho and Leerink Partners, both rating RLMD as "Outperform," suggest confidence in its future potential.

The average twelve-month price forecast for Relmada Therapeutics (RLMD) is $12.00, with a high of $19.00 and a low of $8.00, according to seven Wall Street analysts.

First Majestic Silver has a Strong Buy rating, with a 71.05% probability of outperforming the market in the next three months.

Viridian Therapeutics (VRDN) has a consensus rating of Buy from 11 analysts, with 55% recommending Strong Buy and 36% recommending Buy.

Relmada Therapeutics (RLMD), with a market cap of $91.13 million, is considered a penny stock as it is pre-revenue and unprofitable.

Opendoor Technologies (OPEN) is a digital real estate platform that leverages cloud-based iBuyer services and is increasingly focused on artificial intelligence, reflecting a stabilizing stock price. Although the stock has delivered an impressive one-year return of 303.40%, it has faced challenges, shown by a five-year return of -76.92%. Analysts currently maintain a median price target of $5.50, suggesting a cautious outlook, with expectations for the stock to perform in line with market averages over the next year.

Goldman Sachs holds approximately 2.6 million shares of Opendoor Technologies Inc., representing about 0.3% of the company's outstanding stock.

OPEN stock is expected to perform in line with market averages over the next 12 months.

Analysts have a neutral consensus on OPEN, with a median price target of $4.50, indicating a potential downside from the current price of $5.14.

Terns Pharmaceuticals Inc (TERN) has delivered an impressive one-year return of 1599.36%, signaling strong growth potential. Analysts currently project a median 12-month price target of $56.00, with forecasts ranging from $35.00 to $70.00. Despite recent downgrades from TD Cowen and Citizens, TERN is still viewed positively by the analyst community, with a consensus rating of Buy from nine analysts.

Terns Pharmaceuticals (TERN) has a consensus rating of 'Buy' from 9 analysts.

The average price target for Terns Pharmaceuticals is $58.11, with estimates ranging from $54.00 to $70.00, indicating a potential increase of 21.62% from the last closing price of $47.78.

TERN has a bullish consensus among 16 analysts, with a median price target of $57.00, suggesting a 17.7% upside from its current trading price of $48.44.

TERN's stock price has surged, particularly following the announcement of an acquisition by Merck & Co.